Results 11 to 20 of about 12,197,984 (249)

Rationale for Long-acting Growth Hormone Therapy and Future Aspects [PDF]

JCRPE
Recombinant growth hormone (GH) is administered as daily subcutaneous injections. Daily treatment can be challenging for children/adolescents, as well as for parents and/or caregivers, such as legal representatives or guardians of children in ...
Semra Çetinkaya, Erdal Eren, Furkan Erdoğan, Feyza Darendeliler   +3 more
doaj   +7 more sources

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation [PDF]

Frontiers in Endocrinology, 2022
Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life.
Martin Bidlingmaier, Beverly M.K. Biller, David Clemmons, Jens Otto L. Jørgensen, Hiroshi Nishioka, Yutaka Takahashi, Yutaka Takahashi   +6 more
doaj   +5 more sources

Perspectives on long-acting growth hormone therapy in children and adults [PDF]

Archives of Endocrinology and Metabolism, 2020
Growth hormone therapy with daily injections of recombinant human growth hormone has been available since 1985, and is shown to be safe and effective treatment for short stature in children and for adult growth hormone deficiency. In an effort to produce
Rayhan A. Lal, Andrew R. Hoffman
doaj   +7 more sources

Long-Acting Growth Hormone Preparations and Their Use in Children with Growth Hormone Deficiency [PDF]

Hormone Research in Paediatrics, 2022
<b><i>Background:</i></b> Daily recombinant human growth hormone (rhGH) is approved and marketed worldwide to treat children and adults with GH deficiency and other conditions. Efficacy of rhGH therapy is influenced by several variables.
Pampanini, Valentina, Deodati, Annalisa, Inzaghi, Elena, Cianfarani, Stefano   +3 more
openaire   +4 more sources

Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency. [PDF]

J Endocr Soc
Abstract Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic ...
Albers N, Cadarette S, Feakins B, Arregui M, Ebohon S, Lai P, Raveendran S, Kjelgaard-Hansen M, Andersen C, Zhao C, Smith A, Geffner M.   +11 more
europepmc   +4 more sources

Can long-acting growth hormone improve adherence in pediatric growth hormone deficiency? [PDF]

Endocrine
Abstract Growth hormone deficiency (GHD) in childhood and adolescence requires long-term therapy with recombinant human growth hormone (rhGH). Although daily injections are highly effective, they impose a considerable treatment burden that often leads to suboptimal adherence and compromised growth outcomes.
Rodaro C, Tamaro G, Fachin A, Nicolardi F, Tommasi S, Tornese G.   +5 more
europepmc   +6 more sources

Precision Dosing for Pediatric Growth Hormone Deficiency With Daily and Weekly Growth Hormone [PDF]

MedComm
Pediatric growth hormone deficiency (GHD) typically requires daily injections of recombinant human growth hormone (rhGH). Long‐acting PEGylated recombinant human growth hormone (PEG‐rhGH) formulations have been developed to reduce injection frequency and
Wei Wu, Chun‐Xiu Gong, Jie Mei, Ling Hou, Yan Liang, Yan‐qin Ying, Feng Ye, Ge‐Hang Ju, Hui‐Xiang Tian, Nan Yang, Yun Qin, Dongsheng Ouyang, Xiaoping Luo   +12 more
doaj   +3 more sources

Long-Acting Growth Hormone Therapy in Pediatric Growth Hormone Deficiency: A Consensus Statement.

J Clin Endocrinol Metab
Abstract Context Several long-acting growth hormone (LAGH) therapies have recently become available, but guidance on their usage in children with growth hormone (GH) deficiency is limited. Methods International experts in pediatric ...
Maniatis A, Cutfield W, Dattani M, Deal C, Collett-Solberg PF, Horikawa R, Maghnie M, Miller BS, Polak M, Sävendahl L, Woelfle J.   +10 more
europepmc   +4 more sources

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. [PDF]

Eur J Endocrinol, 2016
Objective The Growth Hormone (GH) Research Society (GRS) convened a workshop to address important issues regarding trial design, efficacy, and safety of long-acting growth hormone preparations (LAGH). Participants A closed meeting of ...
Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, Chanson P, Chatelain P, Choong CS, Clemmons DR, Cohen LE, Cohen P, Frystyk J, Grimberg A, Hasegawa Y, Haymond MW, Ho K, Hoffman AR, Holly JM, Horikawa R, Höybye C, Jorgensen JO, Johannsson G, Juul A, Katznelson L, Kopchick JJ, Lee KO, Lee KW, Luo X, Melmed S, Miller BS, Misra M, Popovic V, Rosenfeld RG, Ross J, Ross RJ, Saenger P, Strasburger CJ, Thorner MO, Werner H, Yuen K.   +40 more
europepmc   +11 more sources

Treatment of a case with short stature and Goltz syndrome with long-acting growth hormone: a case report and follow-up [PDF]

BMC Pediatrics
Goltz syndrome, also known as focal dermal hypoplasia, is an X-linked dominant genetic disorder caused by mutations in the PORCN gene, mainly characterized by developmental impairments affecting the skin, hair, bones, teeth, and eyes.
Jinghui Zhang, Nana Qiao, Xiaochun Li
doaj   +2 more sources